| |
|
|
|
Aeglea BioTherapeutics Inc.  
|
|
7.77 0.17 (0.02%) |
10-16 16:00 |
|
Open: |
7.58 |
Pre close: |
7.6 |
Target:
|
9.61
|
|
High: |
7.84 |
Low: |
7.58 |
Resistance:
|
8.23
8.96
|
|
Volume: |
14,173 |
Market Cap: |
224M |
Support:
|
7.05
5.87
|
|
|
|
|
|
Technical Analysis |
|
Moving Averages |
MA(5):
|
7.65
 |
MACD |
MACD(12,26):
|
-0.13 |
|
MA(20): |
7.72  |
Signal(12,26,9): |
-0.15 |
|
MA(100): |
7.42 |
Stochastic Oscillator |
%K(14,3):
|
46.71 |
|
MA(250): |
7.77 |
%D(3): |
40.22 |
|
Average Volume(K) |
3-Month: |
8254
|
52-Week |
High:
|
10.28 |
|
10-Days: |
3144 |
Low: |
5.99 |
|
RSI |
RSI(14):
|
50.44 |
Change(%): |
-18.8 |
|
Financials, Statistics and Valuation |
|
EPS |
-2.300 |
Return on Equity (ttm) |
-71.7 |
Shares Out. (M) |
28.89 |
|
EPS Est. Current Year |
-2.070 |
Return on Assets (ttm) |
-40.5 |
Shares Float (M) |
16.93 |
|
EPS Est. Next Year |
-2.190 |
PEG Ratio |
0.00 |
% Held by Insiders |
8.07 |
|
EPS Est. Next Quarter |
-0.580 |
Qtrly Rev. Growth |
0.0 |
% Held by Institutions |
67.20 |
|
Forward EPS |
-2.600 |
Gross Profit (p.s.) |
-1.136 |
Shares Short (K) |
370 |
|
Book Value (p.s.) |
3.450 |
EBITDA (p.s.) |
-2.197 |
P/E |
-3.38 |
|
Sales Per Share |
0.000 |
Qtrly Earnings Growth |
0.00 |
P/BV |
2.25 |
|
Profit Margin |
0.00 |
Operating Cash Flow
(M) |
-47.89 |
P/S |
0.00 |
|
Operating Margin |
0.00 |
Levered Free Cash Flow
(M) |
-26.38 |
P/CF |
-4.69 |
|
|
|
|
|
|
